Research References Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
With both injectable and oral medication options, our telehealth model and insurance handling, transitioning to a healthier lifestyle is made seamless
SGLT2i use is associated with an increased risk of DKA and UTI, but confers several favourable outcomes, notably preservation of renal function, reduced risk of developing heart failure and CKD, and of hospitalisation, despite a higher prevalence of heart failure, hypertension, IHD and CKD at baseline
Mix with water and take as a pre- or post-workout supplement
The results showed that semaglutide use was linked to an increased relative risk of ischemic optic neuropathy, but tirzepetide was not
Your activity levels